COMMUNIQUÉ DE PRESSE
News
-
-
-
-
COMMUNIQUÉ DE PRESSE
EQS-Adhoc: Formycon AG publishes preliminary figures for the 2023 financial year and guidance for the 2024 financial year
Formycon AG publishes preliminary figures for 2023 financial year and guidance for 2024. EBITDA expected around EUR 1.5 million for 2023 and revenues of EUR 55-65 million for 2024 -
-
-
COMMUNIQUÉ DE PRESSE
Formycon announces commercial launch of FYB201 (Ranibizumab) in Canada (RanoptoTM) and Switzerland (Ranivisio®)
Formycon announces commercial launch of FYB201 (Ranibizumab) in Canada and Switzerland, expanding availability in 17 countries. Biosimilar offers cost-effective treatment for retinal diseases -
-
-
COMMUNIQUÉ DE PRESSE
Formycon and Fresenius Kabi reach settlement agreement for ustekinumab biosimilar candidate FYB202 in Europe and Canada
Formycon and Fresenius Kabi reach settlement agreement with Johnson & Johnson for ustekinumab biosimilar FYB202 in Europe and Canada. Agreement terms kept confidential. Focus on expanding patient access and ensuring reliable treatment options
